[TODAY] Potential Short-Squeeze?

But check this out… Advertisement | [Unsubscribe]( Something just came across my desk and I have to share it with you immediately. An analyst at one of the oldest and most prestigious firms on Wall Street just published a research report claiming that [this stock could run 366% within the next 12 months](. But check this out… MarketWatch just published its list of the most heavily shorted stocks and this company is in the top 50. (out of over 6,000 publicly listed companies) Benzinga even listed it as one of the “5 Short Squeeze Stocks That Could Soar” After seeing what GameStop did last year, everybody is on the lookout for a good short-squeeze situation. When I pulled up the symbol I was shocked to see how cheap the shares were. [The stock is literally trading for a buck and was just given $3.50 price-target](. The company just announced strong second-quarter 2022 financial results and affirms full-year 2022 guidance after net sales of its leading FDA product increased 42% over the previous 3 months, closing the second quarter with $19.9 million in unrestricted cash. Additionally, the company just completed registrational Phase 3 trials evaluating one of its products for the prevention of infectious diseases with positive outcomes from the topline data expected in October 2022. If I was a short-seller of this company I would be petrified right now. Instead of me telling you all about this company in an email, [you can click here to read the same report that just came across my desk.]( Sincerely, Dollar Stock Club 💲 DISCLAIMERS - THIS IS A PAID ADVERTISEMENT. This is a paid advertisement, not a recommendation nor an offer to buy or sell securities or investments. Our business model is to be financially compensated to market and promote public companies. By reading this email, our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is strictly for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage. Guardian Publishing LLC has received Five Thousand Dollars for and on behalf of Evofem Biosciences, Inc (NASDAQ: EVFM) for brand awareness, marketing distribution and investor education marketing for a period of 1 day. Guardian Publishing has not received any shares nor owns any shares of Evofem Biosciences, Inc (NASDAQ: EVFM) For a full disclaimer | disclosure please [click here.]( This communication is a paid advertisement and is not a recommendation to buy or sell securities or investments. Guardian Publishing, and its owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by a third party, on behalf of Evofem Biosciences, Inc (NASDAQ: EVFM) Five Thousand Dollars for marketing services for a period of 1 day. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict with our ability to be unbiased, more specifically: This communication is strictly for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in this article, in our newsletter and on our website may be based on end-of-day or intraday data. We have been compensated by a third party, Evofem Biosciences, Inc (NASDAQ: EVFM) to conduct investor awareness advertising and marketing. Therefore, this communication should be viewed as a commercial advertisement only. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Guardian Publishing often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, and approved by the company that is featured herein, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. We have not thoroughly investigated the background of Evofem Biosciences, Inc (NASDAQ: EVFM) . The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices. Frequently companies profiled in our alerts experience a large fluctuation in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions. RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are strictly for entertainment purposes only. Never invest purely based on our featured profiles on Companies. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities or investments mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. The past performance of any trading system or methodology is not necessarily indicative of future results. The profits and performance shown are not typical, we make no future earnings claims, and you may lose money. All trades, patterns, charts, systems, etc., discussed in this message and the product materials are strictly for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher. Guardian Financial Publishing 3571 Far West Blvd Austin, TX 78731 United States This email was sent to {EMAIL}. Don't want to receive these emails anymore? [Unsubscribe]( [Privacy Policy]( | [Terms]( | [Risk Disclosure](